Niagen Bioscience (NAGE) Surpasses Q3 Earnings and Revenue Estimates

Core Viewpoint - Niagen Bioscience (NAGE) reported quarterly earnings of $0.05 per share, exceeding the Zacks Consensus Estimate of $0.02 per share, marking a 150% earnings surprise compared to the previous year's earnings of $0.02 per share [1] Financial Performance - The company achieved revenues of $33.99 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 8.58%, and showing an increase from $25.58 million in the same quarter last year [2] - Over the last four quarters, Niagen Bioscience has consistently exceeded consensus EPS estimates [2] Stock Performance - Niagen Bioscience shares have increased approximately 36.3% since the beginning of the year, outperforming the S&P 500's gain of 16.5% [3] Future Outlook - The company's earnings outlook will be crucial for assessing future stock performance, including current consensus earnings expectations for upcoming quarters [4] - The current consensus EPS estimate for the next quarter is $0.02 on revenues of $33.1 million, and for the current fiscal year, it is $0.13 on revenues of $126.4 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Niagen Bioscience belongs, is currently ranked in the top 39% of over 250 Zacks industries, indicating a favorable industry outlook [8]